Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50%

BACKGROUND: Immune checkpoint inhibitors (ICIs) are standard therapies for patients with advanced non-small-cell lung cancer (NSCLC) and a programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%. Tumor mutation burden (TMB) also predicts response to ICIs but is often not available in rea...

Descripción completa

Detalles Bibliográficos
Autores principales: Gainor, J. F., Rizvi, H., Aguilar, E. Jimenez, Skoulidis, F., Yeap, B. Y., Naidoo, J., Khosrowjerdi, S., Mooradian, M., Lydon, C., Illei, P., Zhang, J., Peterson, R., Ricciuti, B., Nishino, M., Roth, J. A., Grishman, J., Anderson, D., Little, B. P., Carter, B. W., Arbour, K., Sauter, J. L., Mino-Kenudson, M., Heymach, J. V., Digumarthy, S., Shaw, A. T., Awad, M. M., Hellmann, M. D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545963/
https://www.ncbi.nlm.nih.gov/pubmed/32067682
http://dx.doi.org/10.1016/j.annonc.2019.11.015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545963/
https://www.ncbi.nlm.nih.gov/pubmed/32067682
http://dx.doi.org/10.1016/j.annonc.2019.11.015

Ejemplares similares